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Charcot-Marie-Tooth disease is a demyelinating peripheral neuropathy and is a heterogeneous
inherited disorder (40 loci have been described so far) affecting peripheral nerves. Two forms,
CMT1A and CMTX, account for 60 and 15% of patients, respectively, with clear familial
transmission (Boerkel et al., 2002).
CMTX is caused by mutations in the GBJ1 gene encoding the synthesis of connexin 32 (Cx32,
Bergoffen et al., 1993), which is a myelin protein related to PNS and CNS (Scherer et al., 1995).
Cx32 is a membrane protein located in gap junctions, which forms hexameric hemichannels called
connexons. However, the mechanism by which anomalies in connexin 32 affect myelination and
function of PNS remains is still unclear. Here, we share our opinion that CamKinase are involved in
the pathophysiology of CMTX and likely involve genomic instability caused by mutations in Gjb1.
CONNEXIN, CAMKII, AND GENOMIC STABILITY
Apart from its role in the synthesis of Cx32, an inappropriate expression of the gene Gjb1
has recently been associated with genomic instability during mitosis (Mones et al., 2012,
www.mitocheck.org) leading to the hypothesis that connexins may be linked, directly or indirectly,
to genomic stability. The literature suggests that at least one signaling pathway is associated with
both phenomena—calcium homeostasis. Indeed, connexin 32 oligomerizes in Schwann cells to
form hemichannels known to facilitate the diffusion of metabolites across the layers of myelin
sheath. It is now established that calmodulin (CaM) can directly bind the C-terminus of Cx32
and regulate gap junction channels (Torok et al., 1997; Ahmad et al., 2001; Dodd et al., 2008;
Stauch et al., 2012). In response to increased intracellular levels of calcium, CaM then binds to
Cx32 channels triggering its closure and allowing the extrusion of Ca2+ via others channels to
maintain calcium homeostasis. (Lurtz et al., 2003) In CMTX, anomalies of Cx32 alter the binding
of CaM, leading to disturbance of calcium homeostasis by maintaining high intracellular calcium
concentrations. (De Vuyst et al., 2006) However, as Cx32 anomalies decreases the binding of CaM,
we can hypothesize an increase of “free” CaM in the presence of high concentrations of calcium
leading to autophosphorylation of CaMKII upon activation by Ca2+ and CaM (Hell Johannes,
2014). Acting via a retrocontrol mechanism, CaMKII can then phosphorylate Cx32, leading to
modulations of the gap junctional communications (Lampe and Lau, 2004; Stauch et al., 2012).
Recently, we have shown that KN93 and KN-62—two inhibitors of reference of CaMKII—could
restore connexin activity (Mones et al., 2014, p. 382), but as the level of phosphorylation of Cx32
has not been measured, we cannot make any conclusions about the mechanism involved in this
overstimulation.
Genomic instability occurs whenmultipolar spindles appear due to centrosome overduplication.
In 2002, Matsumoto and Maller described in Xenopus egg extracts that inactivation of CaMKII
could block centrosome overduplication suggesting that calcium oscillations in the cell may be
linked to centrosome duplication. (Matsumoto and Maller, 2002) Also also Xenopus egg extracts,
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Reber et al. confirmed this hypothesis and showed that calcium or
constitutive active CaMKII promotesmicrotubule destabilization
(Reber et al., 2008). We recently showed that CamKII activity
is overactivated in cells from a mouse model of CMTX
involving mutations in Gjb1 (Mones et al., 2014) and in
cells from CMTX1 patients (Mones et al., 2015). These cells
presented centrosome overduplication and genomic instability.
Interestingly, this cellular phenotype was corrected by treatment
with CamKII inhibitors both in Gjb1-mutatedmouse and human
patient cells (Mones et al., 2014, 2015).
These data suggest that anomalies of Cx32 due to GBJ1
mutations lead to unbalanced calcium homeostasis resulting in
a genomic instability through the overactivation of CaMKII.
CONNEXIN AND MYELIN
Myelin deficit is the first alteration observed in Cx32-deficient
mice, supporting the link between connexin and myelin (Scherer
et al., 1998). Cx32 is the most abundant connexin isoform in
Schwann cells, and it oligomerizes to form gap junction channels
between two cells. However, gap junctions in Schwann cells can
also form intracellular channels through the layers of myelin
providing a direct route for the diffusion of metabolites and
second messengers from the Schwann cell to the axon. This
is likely necessary for myelin formation (Ressot and Bruzzone,
2000). Our recent work with KN93 and KN62, two inhibitors of
CaMKII, concur with this hypothesis because they may block the
CaMKII-mediated phosphorylation of Cx32 and at least partially
restore the activity of the connexon (Mones et al., 2014, 2015).
However, some facts challenge this mechanistic hypothesis.
Indeed, Cx32 is the major component of liver gap junctions, and
CMTX mutations of GJB1 do not result in a severe phenotype in
this organ. Regarding CNS, although patients with central clinical
signs have been reported (Hanemann et al., 2003), the majority of
CMTX patients did not present central clinical signs. However,
they did present infra-clinical and asymptomatic signs. This a
major observation in inherited disorders caused by mutations
in an ubiquitously expressed protein. There is usually no clear
explanation.
CAMKII AND MYELIN
Another hypothesis to explain the CMTX phenotype due to
GJB1 mutations is overactivation of CaMKII. A recent work by
Weggener et al. supports this hypothesis. They showed that a
mouse line invalidated for CamKIIβ gene exhibits a deficit in
myelination in the CNS. The authors suggested that this deficit
is due to anomalies in phosphorylation of cytoskeletal proteins
(Waggener et al., 2013). Earlier, Sahenk et al. reported that CMTX
xenografts where Schwann cells bear mutations on Cx32 were
presenting major cytoskeletal alterations (Sahenk, 1999). While
the link between CaMKII, cytoskeleton anomalies and myelin
deficits may be established, we do not yet know whether the
CaMKII-related genomic instability observed in cell phenotypes
of CMTX patients is part of the same signaling pathway leading
to myelin deficit. However, this hypothesis is interesting because
CMTX-induced genomic instability in the Schwann cells may
affect the PNS myelination in a downstream process occurring
over a long period of time before the appearance of clinical
symptoms. In another form of CMT (CMT1A), infants were
showed to bear the CMT1A mutation, but without clinical
symptoms. They still had a reduced nerve conduction velocity
indicating that a deficit in myelination is already present before
the disease manifests (Garcia and Combarros, 1998).
This begs the question of calcium homeostasis and
myelination. Nobbio et al. demonstrated the impact of
perturbation of calcium homeostasis in a CMT1A model
(Nobbio et al., 2009). This is strengthened by the report of
Stevens et al. demonstrating that perturbation of calcium
homeostasis inhibits differentiation of precursors of Schwann
cells (Stevens and Fields, 2000). In the same report, they
suggested that it involves Ca2+, calmodulin and calmodulin
kinase.
DEMYELINATION AND INFLAMMATION
Several mechanisms are likely co-existing between the primary
causes of the disease (including gene mutation and the resulting
deregulation of the downstream cascade) and the symptomatic
manifestations of the disease (locomotion, fatigue, pain, etc.) In
this field, Martini et al. demonstrated that murine models of
demyelinating CMT present inflammation, in which both innate
and adaptive immune systems would act as amplifiers of the
primarily genetically caused neuropathies (for review, Martini
and Willison, 2016). However, in their putative mechanism,
they argued propose a yet to be identified primary activator
that would lead to myelin phagocytosis by macrophages and
Schwann cell dedifferentiation. The inflammatory process would
be an aggravating factor of the neuropathy. Considering that
inflammation is very frequently associated with degenerative
disorders (Alzheimer’s disease, diabetes . . . ), it is likely that
inflammation acts in clinical picture of demyelinating CMT. The
question of cause or consequence of the disorder is difficult
to answer. However, the assumption that anomalies in tissues
structure (abnormal myelin, decompacted myelin, etc), are
leading to inflammation is very likely.
Our opinion is that inherited demyelinating disorders are
developmental disorders linked to anomalies of Schwann cells
terminal differentiation and myelin formation. However, this
putative role of inappropriate differentiation as the primary cause
of inflammation is still to be proved. In addition, potential
direct links between genomic instability and neuroinflammation
remain still elusive, although Taupin reported an association
between neuroinflammation in Alzheimer disease and genomic
instability (aneuploidy) (Taupin, 2010). We did not find a report
of a similar phenomenon in PNS disorders.
CMTX AND THERAPEUTIC APPROACHES
Therapeutic efficacy requires a good understanding of the
mechanisms involved in the disease. Recent works in the CMTX
field show that there are many questions still pending before this
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genetic disease can be fully understood. Inflammation is certainly
a good target that could lower disease severity including pain.
Targeting upstream events linked to the primary cause of the
disorder would be also a promising track to treat CMTX patients.
Indeed, we have demonstrated that in vitro and in vivo abnormal
phenotypes are corrected in animal models by treatment with
CamKII inhibitors (Mones et al., 2014). In addition, we have
demonstrated that the same anomalies are observed in cells from
CMTX patients and that these anomalies are corrected using
CamKII inhibitors. CaMKII is a common target to the various
mechanistic hypotheses presented earlier. In order to prevent
potential toxicity, development of CaMKIImodulatorsmay allow
down-activation of CaMKII in the PNS without strongly altering
calcium homeostasis in other cells. The CamKII inhibitors KN93
and KN62 have never been tested in humans and deserve a full
optimization process to improve their efficacy toward CamKII.
However, although no toxic evaluation has been reported, no
adverse effect has been reported in animals treated with this
molecule.
The hypothesis dealing with genomic instability and myelin
deficit is also interesting in terms of therapeutic options.
Indeed, several kinases are already known to be involved in
genomic instability. These likely act downstream to CamKinases.
Pim1 is one of these kinases that is involved in genomic
instability in cancer cells (Roh et al., 2003). We have shown
that Pim1 inhibitors can correct genomic instability in GBJ1-
mutated cell lines, but were unable to correct Cx32 activity
(Mones et al., 2014). It would be interesting to test these
Pim1 inhibitors in CMTX mice to evaluate their ability to
restore a normal phenotype, and validate or rule out this
mechanistic hypothesis. Moreover, downstream kinases could be
an additional therapeutic target.
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